{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:23:50Z","timestamp":1786998230948,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.xops.2021.100034","type":"journal-article","created":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T03:59:49Z","timestamp":1624679989000},"page":"100034","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Prospective, Longitudinal Pilot Study"],"prefix":"10.1016","volume":"1","author":[{"given":"Tiarnan D.L.","family":"Keenan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaella","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna","family":"Goldenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1147-444X","authenticated-orcid":false,"given":"Dinah","family":"Zur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiri","family":"Shulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Loewenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.xops.2021.100034_bib1","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/IAE.0000000000000483","article-title":"Identification of fluid on optical coherence tomography by treating ophthalmologists versus a reading center in the Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"35","author":"Toth","year":"2015","journal-title":"Retina"},{"issue":"9","key":"10.1016\/j.xops.2021.100034_bib3","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","article-title":"Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)","volume":"98","author":"Schmidt-Erfurth","year":"2014","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"10.1016\/j.xops.2021.100034_bib4","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/eye.2013.233","article-title":"The Royal College of Ophthalmologists guidelines on AMD: executive summary","volume":"27","author":"Chakravarthy","year":"2013","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.xops.2021.100034_bib5","series-title":"Age-related macular degeneration","year":"2018"},{"issue":"12","key":"10.1016\/j.xops.2021.100034_bib6","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1038\/s41433-020-0799-y","article-title":"Association between visual acuity, lesion activity markers and retreatment decisions in neovascular age-related macular degeneration","volume":"34","author":"Chakravarthy","year":"2020","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.xops.2021.100034_bib7","first-page":"1","article-title":"The patients\u2019 view: age-related macular degeneration and its effects\u2014a meta-synthesis","author":"Thier","year":"2020","journal-title":"Disabil Rehabil"},{"issue":"2","key":"10.1016\/j.xops.2021.100034_bib8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/13548506.2016.1274040","article-title":"Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration","volume":"23","author":"Boyle","year":"2018","journal-title":"Psychol Health Med"},{"issue":"4","key":"10.1016\/j.xops.2021.100034_bib9","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ajo.2015.06.023","article-title":"Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study","volume":"160","author":"Prenner","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.xops.2021.100034_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0129361","article-title":"Caregiver burden in patients receiving ranibizumab therapy for neovascular age related macular degeneration","volume":"10","author":"Gohil","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.xops.2021.100034_bib11","series-title":"Hospital outpatient activity 2019-20","year":"2020"},{"issue":"2","key":"10.1016\/j.xops.2021.100034_bib12","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","article-title":"Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review","volume":"128","author":"Okada","year":"2021","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.xops.2021.100034_bib13","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.oret.2020.05.015","article-title":"Management of neovascular age-related macular degeneration during the COVID-19 pandemic","volume":"4","author":"Corradetti","year":"2020","journal-title":"Ophthalmol Retina"},{"issue":"7821","key":"10.1016\/j.xops.2021.100034_bib14","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.xops.2021.100034_bib15","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ajo.2020.12.012","article-title":"Automated quantitative assessment of retinal fluid volumes as important biomarkers in neovascular age-related macular degeneration","volume":"224","author":"Keenan","year":"2021","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"10.1016\/j.xops.2021.100034_bib16","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3390\/pharmaceutics11080365","article-title":"Pharmacokinetics of intravitreal anti-VEGF drugs in age-related macular degeneration","volume":"11","author":"Garcia-Quintanilla","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xops.2021.100034_bib17","first-page":"CD012208","article-title":"Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration","volume":"5","author":"Li","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.xops.2021.100034_bib18","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ajo.2018.05.026","article-title":"The treat-and-extend injection regimen versus alternate dosing strategies in age-related macular degeneration: a systematic review and meta-analysis","volume":"192","author":"Okada","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.xops.2021.100034_bib19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ajo.2009.01.024","article-title":"A\u00a0variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study","volume":"148","author":"Lalwani","year":"2009","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.xops.2021.100034_bib20","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ajo.2007.02.024","article-title":"Ranibizumab according to need: a treatment for age-related macular degeneration","volume":"143","author":"Spaide","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"10.1016\/j.xops.2021.100034_bib21","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"issue":"9900","key":"10.1016\/j.xops.2021.100034_bib22","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","article-title":"Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial","volume":"382","author":"Chakravarthy","year":"2013","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.xops.2021.100034_bib23","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/eye.2017.67","article-title":"A\u00a0systematic review to assess the \u2018treat-and-extend\u2019 dosing regimen for neovascular age-related macular degeneration using ranibizumab","volume":"31","author":"Rufai","year":"2017","journal-title":"Eye (Lond)"},{"issue":"12","key":"10.1016\/j.xops.2021.100034_bib24","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.oret.2019.11.004","article-title":"Nonresponders to ranibizumab anti-VEGF treatment are actually short-term responders: a prospective spectral-domain OCT study","volume":"4","author":"Bontzos","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2021.100034_bib25","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.preteyeres.2017.12.002","article-title":"Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors","volume":"65","author":"Mehta","year":"2018","journal-title":"Prog Retin Eye Res"},{"issue":"11","key":"10.1016\/j.xops.2021.100034_bib26","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3928\/23258160-20201104-05","article-title":"Baseline visual acuity at wet AMD diagnosis predicts long-term vision outcomes: an analysis of the IRIS Registry","volume":"51","author":"Ho","year":"2020","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.xops.2021.100034_bib27","doi-asserted-by":"crossref","unstructured":"Khanani AM, Callanan D, Dreyer R, et\u00a0al. End of study results for the Ladder phase 2 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmol Retina. 2020 Nov 18;S2468-6530(20)30447-4. https:\/\/doi.org\/10.1016\/j.oret.2020.11.004. Online ahead of print.","DOI":"10.1016\/j.oret.2020.11.004"},{"issue":"41","key":"10.1016\/j.xops.2021.100034_bib28","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.2174\/1381612825666190123165216","article-title":"Novel long-acting pharmacotherapy for exudative age related macular degeneration","volume":"24","author":"Moisseiev","year":"2018","journal-title":"Curr Pharm Des"},{"issue":"15","key":"10.1016\/j.xops.2021.100034_bib29","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1080\/14656566.2019.1636031","article-title":"Innovative therapies for neovascular age-related macular degeneration","volume":"20","author":"Al-Khersan","year":"2019","journal-title":"Expert Opin Pharmacother"},{"issue":"12","key":"10.1016\/j.xops.2021.100034_bib30","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1055\/a-1271-6834","article-title":"Evaluation of a self-imaging SD-OCT system for remote monitoring of patients with neovascular age related macular degeneration","volume":"237","author":"Nahen","year":"2020","journal-title":"Klin Monbl Augenheilkd"},{"key":"10.1016\/j.xops.2021.100034_bib31","unstructured":"Loewenstein A, Goldstein M, Goldenberg D, et al. Quality of retinal images captured by a self-operated, home-based optical coherence tomography (OCT) system. American Academy of Ophthalmology 2020 Meeting; 2020. Available at: https:\/\/aao.scientificposters.com\/epsAbstractAAO.cfm?id=1"},{"key":"10.1016\/j.xops.2021.100034_bib32","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ophtha.2020.06.038","article-title":"Retinal specialist vs artificial intelligence detection of retinal fluid from optical coherence tomography: AREDS2 10-year follow-on","volume":"128","author":"Keenan","year":"2021","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.xops.2021.100034_bib33","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.ophtha.2016.04.005","article-title":"Automated identification of lesion activity in neovascular age-related macular degeneration","volume":"123","author":"Chakravarthy","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2021.100034_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/s41433-020-01354-4","article-title":"Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD","author":"Chakravarthy","year":"2021","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.xops.2021.100034_bib35","unstructured":"Kim JE. Performance of a novel deep learning algorithm for automatic retinal fluid quantification in home OCT images. American Society of Retina Specialists Annual Scientific Meeting; 2020."},{"issue":"5","key":"10.1016\/j.xops.2021.100034_bib36","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ophtha.2018.11.025","article-title":"Tolerating subretinal fluid in neovascular age-related macular degeneration treated with ranibizumab using a treat-and-extend regimen: FLUID study 24-month results","volume":"126","author":"Guymer","year":"2019","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.xops.2021.100034_bib37","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s00417-020-05035-6","article-title":"Self-examination low-cost full-field OCT (SELFF-OCT) for patients with various macular diseases","volume":"259","author":"von der Burchard","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"10.1016\/j.xops.2021.100034_bib38","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1167\/tvst.7.4.8","article-title":"Safety and feasibility of a novel sparse optical coherence tomography device for patient-delivered retina home monitoring","volume":"7","author":"Maloca","year":"2018","journal-title":"Transl Vis Sci Technol"},{"issue":"1","key":"10.1016\/j.xops.2021.100034_bib39","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41433-020-01263-6","article-title":"Optical coherence tomography in the 2020s-outside the eye clinic","volume":"35","author":"Chopra","year":"2021","journal-title":"Eye (Lond)"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914521000324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914521000324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T06:18:53Z","timestamp":1763014733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666914521000324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S2666914521000324"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2021.100034","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prospective, Longitudinal Pilot Study","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2021.100034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"100034"}}